The genetic deletion of TRF1 impairs tumor initiation and progression in various mouse GBM subtypes by inducing telomere damage and reducing stemness in glioma stem cells, validating TRF1 as a favorable target in glioblastoma treatment [112]. The gene discussed is TERF1; the disease is glioblastoma.